91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Despite decades of progress transforming HIV from a fatal diagnosis into a manageable chronic condition, today’s antiretroviral therapies still face a stubborn barrier: They work brilliantly in theory but fall short when access, adherence, and real-world challenges get in the way.
-
The transformative impact of complex biopharmaceuticals hinges on integrating advanced delivery systems, often accelerated by AI modeling, with robust manufacturing practices and regulatory alignment to ensure stability, safety, and effective patient access.
-
The regulatory landscape is being rewritten. The future belongs to those who anticipate, adapt and act with purpose. In this article we look at 3 macro trends that are redefining regulatory strategy.
-
This article explores the landscape, regulatory considerations, infrastructural and operational requirements along with future directions for expanding Radiopharmaceuticals and Theranostics therapies into clinical settings.
-
As antibiotic resistance surges globally, bacteriophage therapy is emerging as a promising alternative for treating multidrug-resistant infections. To scale this life-saving approach, investment in phage development, clinical trials, and diagnostic infrastructure is urgently needed.
-
The article, featuring commentary from Nagalakshmi Shetty, highlights how India's clinical research sector is rapidly expanding. Regulatory reforms like the Central Drugs Standard Control Organisation's NDCR (Amendment) Rules 2024, mandatory CRO registration and digitised portals are boosting transparency, shortening approval timelines and positioning India as a global hub for clinical trials.
-
In this PharmaTimes article, Nagalakshmi Shetty explores how clinical data science is evolving from traditional management toward intelligent, risk-based, patient-centric research frameworks.
-
Explore how industry leaders are overcoming manufacturing and regulatory hurdles to scale CAR-T cell therapies across Asia-Pacific.
-
91黑料 have been included in Forbes' list of only 400 global companies. Based on a survey of approximately 120,000 women in more than 36 countries, positions were awarded to companies that have been identified as top performers in promoting gender equality and supporting women in the workplace.
-
AI is redefining oncology biomarker discovery, unlocking new precision in patient selection and trial design. Explore how this evolving technology is shaping the future of cancer drug development.
